INTRODUCTION {#s1}
============

Breast cancer is the most frequent malignancy among women. Almost 16,000 of women in Poland are diagnosed annually with breast cancer; the death toll is greater than 5,000. It is estimated that this annual morbidity may rise up to 20 thousand women in 2020 \[[@R1], [@R2]\]. Following the latest data of Eurocare-5, a five-year survival is achieved by 71.6% of female patients in Poland vs. 82% of the mean European value. Regarding breast cancer, the percent of successful 5-year treatment outcomes in Poland is 10% lower than the EU average \[[@R3]\].

Breast cancer is characterized by the occurrence of different genetic changes in various genes \[[@R4]--[@R6]\]. Consequently, it is often not possible to give a straightforward answer to the question, whether these changes are more like causes or more like effects of the disease. If they are perceive as causes, it is justified to study if the genetic variability, observed in many populations and defined as genetic polymorphism, may in any way contribute to induction and/or development of malignant changes, including breast cancer. Breast cancer is a disease with significant genetic component, characterized by high cure rates with early diagnosis \[[@R7]--[@R9]\]. This is the reason why prophylactic examinations of subjects from the group with high genetic risk would facilitate early diagnosis, eventually leading to reduced mortality rates \[[@R7]--[@R9]\]. DNA repair is a part of the barriers, protecting from cancer forming mutations \[[@R10]--[@R12]\]. Following the results of studies, cancer diseases are driven by a compromised ability of DNA repair. Therefore, a set of alleles of repair protein encoding genes may largely define the individual abilities for DNA damage repair, as well as the susceptibility to tumor development. It is then important to learn the polymorphic variants of the genes, associated with DNA repairs, as well as with their degradation in their population. The single nucleotide polymorphisms (SNPs) may change the risk of cancer. SNPs may then be regarded as potential markers of carcinogenesis \[[@R13], [@R14]\].

In our research projects, we concentrated on an evaluation of the role of single nucleotide polymorphisms of DNA repair genes in the pathogenesis of breast cancer and in the prognosis of its further course. The primary objectives of our studies were to identify the SNPs, associated with the risk of breast cancer in women of the Polish population, and to estimate the risk of their carrier-state. The results of our studies may help better understand the molecular background of the disease formation and enable to evaluate the probability of its occurrence in specific subjects of the population. The polymorphisms of DNA repair genes were selected on the basis of literature data, which are highly suggestive of their correlations with cancers development.

The alternations in DNA mismatch repair (MMR) genes have been associated with cancers development. *hMSH2* (MutS protein homolog 2) gene is involved in the MMR system \[[@R15]\]. Following data from the world literature, Gly322Asp polymorphism of *hMSH2* gene may enhance the risk of malignancy in the colon or the stomach, as well as increase the incidence rate of lymphomas, anaemia and breast cancer \[[@R16]--[@R22]\]. Breast cancer risk may be correlated with endogenous oestrogens \[[@R23]\]. Oestrogens induce DNA damage by producing reactive oxygen species during metabolic reactions \[[@R24]\]. The oestrogens may bring about oxidative DNA defects, which are eliminated by the base excision repair (BER) and nucleotide excision repair (NER) systems. X-ray repair cross-complementing 1 (*XRCC1*) gene is involved in the BER pathway \[[@R25]\]. The Arg399Gln polymorphism of *XRCC1* gene was selected on the basis of literature data, which are highly suggestive of its correlations with breast cancer development \[[@R26]--[@R28]\]. Oestrogens are genotoxic and influence carcinogenesis by the formation of bulky DNA adducts \[[@R29]\]. This type of damage is generally repaired by the nucleotide excision repair (NER) pathway. The *XPD* (the xeroderma pigmentosum group D) gene is involved in the NER pathway \[[@R30], [@R31]\]. The Lys751Gln (rs13181) polymorphism is one of the most widely studied genetic markers in *XPD* and its role in cancer development is evident \[[@R31]\]. Homologous recombination repair (HR) is also involved in the repair of DNA-protein cross-links in cooperation with NER. *XRCC2* and *RAD51* genes are key components of homologous recombination. According to literature data, the most frequently studied single nucleotide polymorphism of *XRCC2* gene is Arg188His. It has been demonstrated in a number of reports that it plays a significant role in the development of neoplastic diseases, including breast cancer \[[@R32]--[@R35]\]. Earlier reports of many researchers, dealing with SNPs in *RAD51* gene concentrated mainly on G135C and G172T polymorphisms at 5′ region, not subject of translation \[[@R36]--[@R40]\]. Our assumption was such that another genetic variability could act either additively or independently of the above-mentioned polymorphisms in 5′UTR region, what may help explain the role of *RAD51* in breast cancer development. Our research was then oriented towards less investigated SNPs within *RAD51* promoter gene: -4719A/T (rs2619679) and -4601A/G (rs5030789).

We examined 300 female patients with breast cancer and 300 healthy women for polymorphisms of the genes, belonging to: - the BER system *XRCC1* gene - Arg399Gln polymorphism (rs25487), - the NER system *XPD* gene - Lys751Gln polymorphism (rs13181), - the MMR system *hMSH2* gene - Gly322Asp (rs4987188), - the HR system *XRCC2* gene Arg188His (rs3218536), *RAD51* gene -4719A/T (rs2619679) and *RAD51* gene -4601A/G (rs5030789).

RESULTS {#s2}
=======

In the studies on a series of 300 DNA samples from patients with breast cancer, originating from an ethnically homogenous population, we found a relationship of the studied polymorphisms with breast cancer occurrence (Table [1](#T1){ref-type="table"}).

###### Frequency distribution of the DNA repair genes genotypes/alleles in patients and controls, and the risk of breast cancer

                      Patients (*n* = 300)   Controls (*n* = 300)                                        
  ------------------- ---------------------- ---------------------- -------- ------- ------------------- -----------
  Arg/Arg             34                     11.33                  66       22.00   1.00 Ref            
  Arg/Gln             38                     12.67                  180      60.00   0.41 (0.23-0.70)    0.0017
  Gln/Gln             228                    76.00                  54       18.00   8.19 (4.92-13.63)   \<.0001
  Arg                 106                    17.67                  312      52.00   1.00 Ref            
  Gln                 494                    82.33                  288      48.00   6.37 (4.86-8.35)    \<.0001
  *hMSH2*-Gly322Asp   Number                 (%)                    Number   (%)     OR (95% CI)         *p*-value
  Gly/Gly             42                     14.00                  80       26.67   1.00 Ref            
  Gly/Asp             51                     17.00                  177      59.00   0.54 (0.33-0.89)    0.021
  Asp/Asp             207                    69.00                  43       14.33   9.16 (5.57-15.07)   \<.0001
  Gly                 135                    22.5                   337      56.17   1.00 Ref            
  Asp                 465                    77.5                   263      43.83   4.41 (3.43-5.67)    \<.0001
  *XPD*-Lys751Gln     Number                 (%)                    Number   (%)     OR (95% CI)         *p*-value
  Lys/Lys             54                     18.00                  96       32.00   1.00 Ref            
  Lys/Gln             70                     23.33                  120      40.00   1.03 (0.66-1.37)    1.000
  Gln/Gln             176                    58.67                  84       28.00   3.72 (2.44-5.68)    \<.0001
  Lys                 178                    29.67                  312      52.00   1.00 Ref            
  Gln                 422                    70.33                  288      48.00   2.56 (2.02-3.25)    \<.0001
  *XRCC2*-Arg188His   Number                 (%)                    Number   (%)     OR (95% CI)         *p*-value
  Arg/Arg             72                     24.00                  80       26.67   1.00 Ref            
  Arg/His             110                    36.67                  106      35.33   1.15 (0.76-1.74)    0.571
  His/His             118                    39.33                  114      38.00   1.15 (0.76-1.73)    0.571
  Arg                 254                    42.33                  266      44.33   1.00 Ref            
  His                 346                    57.67                  334      55.67   1.08 (0.86-1.36)    0.521
  *RAD51*-4719A/T     Number                 (%)                    Number   (%)     OR (95% CI)         *p*-value
  A/A                 60                     20.00                  75       25.00   1.00 Ref            
  A/T                 126                    42.00                  150      50.00   1.05 (0.69-1.58)    0.887
  T/T                 114                    38.00                  75       25.00   1.90 (1.21-2.97)    0.007
  A                   246                    41.00                  300      50.00   1.00 Ref            
  T                   354                    59.00                  300      50.00   1.44 (1.15-1.80)    0.002
  *RAD51*-4601A/G     Number                 (%)                    Number   (%)     OR (95% CI)         *p*-value
  A/A                 78                     26.00                  87       29.00   1.00 Ref            
  A/G                 138                    46.00                  123      41.00   1.25 (0.84-1.84)    0.305
  G/G                 84                     28.00                  90       30.00   1.04 (0.67-1.59)    0.920
  A                   294                    49.00                  297      49.50   1.00 Ref            
  G                   306                    51.00                  303      50.50   1.02 (0.81-1.27)    0.920

^a^Crude odds ratio (OR), 95% CI = confidence interval at 95%.

This study demonstrated that *XRCC1*-Gln/Gln genotype of Arg399Gln polymorphism was strongly correlated with breast cancer. The Gln/Gln homozygote increased the risk of cancer (OR 8.19). The Gln allele in those patients may be a risk factor for breast cancer (OR 6.37; 95% CI 4.86--8.35, *p* \< .0001).

The studies successfully demonstrated that *hMSH2*- Asp/Asp (OR 9.16; 95% CI 5.57--15.07, *p* \< .0001), XPD-Gln/Gln (OR 3.72; 95% CI 2.44--5.68, *p* \< .0001) and RAD51-T/T genotypes (OR 1.90; 95% CI 1.21--2.97, *p* = 0.007) were strongly associated with an increased risk of breast cancer.

In addition, the alleles of *hMSH2*-Asp (OR 4.41; 95% CI 3.43--5.67, *p* \< .0001), *XPD* -Gln (OR 2.56; 95% CI 2.02--3.25, *p* \< .0001) and *RAD51*-T genes (OR 1.44; 95% CI 1.15--1.80, *p* = 0.002) are strongly correlated with breast cancer.

No statistically significant differences were observed in genotype frequencies of *XRCC2* Arg188His polymorphism and *RAD51* -4601A/G polymorphism between the group of patients and healthy controls. (Table [3](#T3){ref-type="table"}).

No relationship was observed between the studied polymorphisms and the cancer progression grade acc. to Scarf-Bloom-Richardson classification.

We did not find any correlation between the studies polymorphic variants of the repair genes and tumour grade or the lymph node status. Neither was there any relationship demonstrated between the analysed polymorphisms and the status of the oestrogen (ER), progesterone (PR) or HER2 receptors. DNA repair genes polymorphisms were also unrelated to the patients age, Hormone replacement therapy (HRT), BMI or menopause status.

DISCUSSION {#s3}
==========

Our works fit in the general trend of studies, based on the commonly accepted and actual concept, assuming that the predisposition to cancers, including breast cancer, may be multigene in character, involving a relatively high number of low-penetration genes. In our studies, the groups of patients were ethnically uniform: female of the Polish origin, inhabitants of the Lodz Region.

We concentrated on an analysis of the relationship between Gly322Asp polymorphism of *hMSH2* gene and breast cancer. We selected the gene for its documented participation in the pathogenesis of cancers. Following data from the world literature, Gly322Asp polymorphism of *hMSH2* gene may enhance the risk of malignancy in the colon or the stomach, as well as increase the incidence rate of lymphomas, anaemia and breast cancer \[[@R41]--[@R43]\].

The Asp allele of Gly322Asp polymorphism was strongly correlated with breast cancer. The Gly322Asp polymorphism affected the tumour grade and size, as well as was associated with the lymph node status.

As literature data demonstrate DNA damages to be highly significant in the pathogenesis of breast cancer, especially those which require repair by homologous recombination \[[@R44], [@R45]\].

Therefore, our studies were continued in an analysis of subsequent polymorphisms in the gene, which encoded the protein, participating in repair by homologous recombination (*RAD51*).

We demonstrated a possible correlation of -4719A/T (rs2619679) and -4601A/G (rs5030789) polymorphisms of *RAD51* repair gene with breast cancer. Earlier reports of many researchers, dealing with SNPs in *RAD51* gene concentrated mainly on G135C and G172T polymorphisms at 5′ region, not subject of translation \[[@R46]--[@R49]\].

Since RAD51 participates in DNA repair, while also interacting with BRCA proteins, the mutations of which are often identified in breast cancer, the above-mentioned polymorphisms may be associated with a higher risk of this cancer development \[[@R50], [@R51]\].

It has been found, among others, that 135C variant may increase the risk of breast cancer in carriers of mutations in *BRCA1* and *BRCA2* genes, while no effects of 135C variant were observed on the morbidity level in women without the mutations. G135C polymorphism can modify the way of mRNA splicing, what, in turn, affects the protein functions or the effectiveness of translation \[[@R52]\].

Despite the abundance of results, there is still no unequivocal explanation of the role of RAD51 in cancer formation. Our assumption was such that another genetic variability could act either additively or independently of the above-mentioned polymorphisms in 5′UTR region, what may help explain the role of RAD51 in breast cancer development \[[@R46], [@R53], [@R54]\].

Our research was then oriented towards less investigated SNPs within *RAD51* promoter gene: -4719A/T (rs2619679) and -4601A/G (rs5030789). We describe a group of 300 female patients with breast cancer, demonstrating that TT genotype of -4719A/T polymorphism and GG genotype of -4601A/G polymorphism of *RAD51* gene was strongly correlated with breast cancer. Moreover, the AG heterozygote of -4601A/G polymorphism of *RAD51* gene was more frequently observed in the first grade of the cancer disease (acc. to Scarf-Bloom-Richardson) than in stage II and III. None of the studied polymorphisms were associated with tumour size or the lymph node status.

The presented studies demonstrated that *XRCC1*--Gln/Gln and *XPD*-Gln/Gln genotypes were strongly associated with an increased risk of breast cancer.

We did not find any correlation between the studies polymorphic variants of the repair genes and tumour grade or tumour size or the lymph node status. Neither did we show any relationship of the analysed polymorphisms with the age of the patients, BMI, hormone replacement therapy or menopausal status.

In summation, the above presented studies contribute to a better knowledge of the molecular background of breast cancer. The results indicate DNA repair genes and their polymorphisms can be involved in the breast cancer formation process in the population of women in Poland. They may find practical application to improve the early diagnostics of cancer and thus to extend the survival rates of women with breast cancer.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

Blood samples were obtained from women with breast carcinoma (*n* = 300), treated at the Department of Department of Oncological Surgery and Breast Diseases, Institute of Polish Mothers Memorial Hospital. Blood specimens were collected from the patients by venipuncture before treatment. The criteria for patient participation in this study were as follows: histologically confirmed diagnosis of breast carcinoma, primary surgical resection of the breast without receiving prior immuno-, radio- or chemotherapy, absence of distant metastases. All the diagnosed tumors were graded by criteria of Scarf-Bloom-Richardson. The age of the patients ranged in from 48 to 84 years (the mean age 57.2 ± 10.12). 300 age-matched disease-free women were selected as controls (age range 49--80, mean age 55.26 ± 10.17). The full characteristics of the study group are presented in Table [2](#T2){ref-type="table"}. The Local Ethic Committee approved the study and each patient gave a written consent (Approval number, 10/2012).

###### The characteristics of breast cancer cases (*n* = 300) and controls (*n* = 300)

                                      Patients (*n*, %)   Controls (*n*, %)
  ----------------------------------- ------------------- -------------------
  Premenopausal                       112 (37.33)         98 (32.67)
  Postmenopausal                      188 (62.67)         202 (67.33)
  Body mass index (BMI ≥ 30 kg/m2)                        
  Yes                                 140 (46.67)         100 (33.33)
  No                                  160 (53.33)         200 (66.67)
  Hormone replacement therapy (HRT)                       
  Never                               114 (38.00)         120 (40.00)
  Estrogen                            186 (62.00)         180 (60.00)
  Hormone receptor status                                 
  ER+                                 72 (24.00)          
  PR+                                 79 (26.33)          
  HER2+                               110 (36.67)         
  ER+PR+HER2+                         19 (6.33)           
  ER-PR-HER2                          20 (6.67)           
  Histopathological grading                               
  G1                                  90 (30.00)          
  G2                                  110 (37.00)         
  G3                                  100 (33.00)         
  Tumor size grade                                        
  T1                                  75 (25.00)          
  T2                                  135 (45.00)         
  T3                                  90 (30.00)          
  Lymph node status                                       
  N0                                  90 (30.00)          
  N1                                  85 (28.33)          
  N2                                  75 (25.00)          
  N3                                  50 (16.67)          

DNA isolation and genotyping {#s4_2}
----------------------------

Genomic DNA was prepared using QIAamp DNA Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer instruction. Real-time PCR cycling and conditions and primers for HRM analysis of all the examined DNA repair SNPs are summarized in Table [3](#T3){ref-type="table"}. CR amplification was performed with support of a Light Cycler^®^ 480 High Resolution Melting Master Kit (Roche, Mannheim, Germany), according to the manufacturer\'s recommendations. The HRM technique was carried out in a LightCycler^®^ 96 (Roche, Mannheim, Germany) Thermocycler. A non-template control contained water, instead of genomic DNA, as a negative control. Additionally, positive controls (DNA samples with known genotype) were employed in each run of HRM analysis. All the control DNA samples were employed in each run of HRM analysis. The collected data were analyzed, using the LightCycler^®^ 96 software version SW 1.1 (Roche, Mannheim, Germany). SNPs in DNA repair genes were selected using the public domain of the National Center for Biotechnology Information at <http://www.ncbi.nlm.nih.gov/snp> (Bethesda, MD, USA). Primer3 software (<http://frodo.wi.mit.edu/,> Tartu, Estonia) was used for primers design.

###### The refSNP and thermal conditions for HRM analysis

  ----------------------------------------------------------------------------------------------------
            Polymorphism   refSNP      Primer sequence\                 Thermal conditions
                                       F-forward, R-reverse             
  --------- -------------- ----------- -------------------------------- ------------------------------
  *XRCC1*   Arg399Gln      rs25487     F 5′-TAAGGAGTGGGTGCTGGACT-3′\    PCR cycling (40 cycles)\
                                       R 5′-ATTGCCCAGCACAGGATAAG-3′     Denaturation 30 s for 95° C\
                                                                        Annealing 30 s for 58° C\
                                                                        Extension 30 s for 72° C\
                                                                        HRM 75--90° C

  *hMSH2*   Gly322Asp      rs4987188   F 5′-GTTTTCACTAATGAGCTTGC-3′\    PCR cycling (40 cycles)\
                                       R 5′-AGTGGTATAATCATGTGGGT-3′     Denaturation 30 s for 95° C\
                                                                        Annealing 30 s for 55° C\
                                                                        Extension 30 s for 72° C\
                                                                        HRM 75--90° C

  *XPD*     Lys751Gln      rs13181     F 5′-CCTCTGTTCTCTGCAGGAGGA-3′\   PCR cycling (40 cycles)\
                                       R 5′-CCTGCGATTAAAGGCTGTGGA-3′    Denaturation 30 s for 95° C\
                                                                        Annealing 30 s for 55° C\
                                                                        Extension 30 s for 72° C\
                                                                        HRM 75--90° C

  *XRCC2*   Arg188His      rs3218536   F 5′-TGTAGTCACCCATCTCTCTGC-3′\   PCR cycling (40 cycles)\
                                       R 5′-AGTTGCTGCCATGCCTTACA-3′     Denaturation 30 s for 95° C\
                                                                        Annealing 30 s for 56° C\
                                                                        Extension 30 s for 72° C\
                                                                        HRM 75--90° C

  *RAD51*   -4719A/T       rs2619679   F 5′-AGATAAACCTGGCCAACGTG-3′\    PCR cycling (40 cycles)\
                                       R 5′-CCGTGCAGGCCTTATATGAT-3′     Denaturation 30 s for 95° C\
                                                                        Annealing 30 s for 57° C\
                                                                        Extension 30 s for 72° C\
                                                                        HRM 75--90° C

  *RAD51*   -4601A/G       rs5030789   F 5′-AGATAAACCTGGCCAACGTG-3′\    PCR cycling (40 cycles)\
                                       R 5′-CCGTGCAGGCCTTATATGAT-3′     Denaturation 30 s for 95° C\
                                                                        Annealing 30 s for 58° C\
                                                                        Extension 30 s for 72° C\
                                                                        HRM 75--90° C
  ----------------------------------------------------------------------------------------------------

Statistical analysis {#s4_3}
--------------------

Genotype and allele distributions were compared with those expected for a population in Hardy-Weinberg equilibrium (HWE) by using the Chi-square test. Genotype and allele frequencies in cases and controls were compared by χ^2^-test. Genotype and allele evaluation, regarding their relationship with a given feature, e.g., a risk for disease, was supported by an analysis of odds ratio (ORs) and 95% confidence intervals, calculated according to the logistic regression model. The wild type of genotype and allele was a reference group. *P*-values \< 0.05 were considered significant.
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